26Oct/18

The Success of Seattle Genetics/Wutian ADC Adcetris for Phase III Clinical Surgery of Peripheral T Cell Lymphoma (PTCL)

October 03, 2018 – Seattle Genetics and Takeda recently announced the evaluation of antibody conjugates Adcetris (brentuximab vedotin) for the treatment of peripheral T-cell lymphoma (PTCL, also known as mature Phase IIIRead More…

01Sep/18

Seattle Genetics Launched the Phase II Clinical Trial of Antibody-drug Conjugate (ADC) Called Enfortumab Vedotin

Seattle Genetics and its partner, Astellas, have recently announced that the patients were selected for EV-201, the key phase II clinical trial of an experimental antibody-drug conjugate (ADC) called enfortumab vedotin. TheRead More…

21Jul/18
What is ADC

Creative Biolabs’s Expert Advanced Professional Opinions in an Exclusive Interview with Biocompare

Recently, Yuning Chen, Ph.D., from Creative Biolabs was exclusively interviewed by  Angelo DePalma, a journalist from Biocompare,  and shared his forward-looking and professional view on antibody-drug conjugates( ADCs). Antibody-drug conjugates (ADCs) are a new implementationRead More…

15Jun/18

Forward I Phase III Trial of Mirvetuximab Sorvtansine in Platinum-resistant Ovarian Cancer Completes Full Enrollment

The FORWARD I Phase III registration trial (NCT02631876) evaluating the antibody-drug conjugate or ADC mirvetuximab soravtansine as a single-agent therapy for the treatment of platinum-resistant ovarian cancer, has completed full enrollment andRead More…